Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER (oxymorphone hydrochloride extended...
The FDA has approved a new, harder-to-abuse formulation of Opana ER, the extended-release oxymorphone drug that is crush resistant from...
The FDA has requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market....
Endo International plc announced that based on an August 11, 2016 discussion with the FDA, the Company has decided to...
Pain Therapeutics, Inc., a drug development company, today announced that a joint meeting of the Anesthetic and Analgesic Drug Products...
Endo International plc announced that it has entered into an agreement with its partner, BioDelivery Sciences International, Inc. (BDSI), to...